Navigation Links
Cardiome And Astellas Announce Positive Results From ACT 2 Trial

) who converted to normal heart rhythm within 90 minutes, the median time to conversion was 12 minutes from the initiation of dosing.

"We are delighted to see a 47% conversion rate in post-operative atrial fibrillation patients, and in particular we are encouraged by the safety profile observed in this fragile patient population," stated Bob Rieder, Chief Executive Officer and Chairman of Cardiome. "The efficacy and safety results observed in this study are consistent with those we've seen throughout the vernakalant (iv) development program."

The ACT 2 study was conducted in 42 centres in the United States, Canada, Argentina, India and Europe. The study was focused on the treatment of patients with atrial fibrillation or atrial flutter occurring after CABG or valve replacement surgery. Approximately 30% of these patients have an episode of atrial arrhythmia following their surgery. The arrhythmia, though transient, is a significant medical concern.

"We are very pleased with the results of the ACT 2 trial and the important insight it provides about the use of vernakalant (iv)," stated Yoshihiko Hatanaka, President and Chief Executive Officer of Astellas Pharma US, Inc.

In October 2003, Cardiome granted Astellas Pharma US, Inc. an exclusive license to develop and commercialize vernakalant (iv) in North America. The companies have co-developed vernakalant (iv) to NDA, with Astellas responsible for 75% of development costs. Cardiome has retained all rights to the intravenous formulations outside of Canada, U.S. and Mexico.

Cardiome will hold a conference call and webcast on Monday, June 4, 2007 at 9:00am EDT (6:00am PDT). Please dial 416-340-8010 or 866-540-8136 to access the call. There will be a separate dial-in line for analysts on which we will respond to questions at the end of the presentation. The webcast can be accessed through Cardiome's website at www.cardiome.com. Webca
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Cardiome And Astellas Announce Positive Results From ACT Trial
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium Research ... market intelligence, the United States ... device markets will expand moderately through 2022, with ... In particular, increasing interest in drug-eluting beads (DEBs) ...
(Date:1/15/2014)... , Jan. 15, 2014 ... research report is available in its ... Markets and Technologies for Advanced Drug ... of Administration ...
(Date:1/14/2014)... , Jan. 14, 2014 InformEx, North ... sellers of high-value chemistry, will hold the 30 th ... Beach Convention Center from January 21-24. ... attendees from top pharmaceutical, fine chemical and specialty chemical companies ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... 2011 /PRNewswire-Asia-FirstCall/ -- DK Sinopharma, Inc. (OTC Bulletin Board: ... that it will present at the Rodman & Renshaw Annual ... the Le Royal Meridien Shanghai in Shanghai, China. ... present on behalf of the Company on Tuesday, March 8, ...
... AORN Works , a subsidiary of the ... market research and surgical insights division will lead the ... http://photos.prnewswire.com/prnh/20101001/DC75398LOGO ) On behalf of ... professionals who are the end users of medical products ...
Cached Medicine Technology:DK Sinopharma, Inc. is to Present at the Rodman & Renshaw Annual China Investment Conference to be Held March 6--8 2Advanced Market Research for Medical Device Manufacturers 2
(Date:4/17/2014)... variant specifically associated with the risk of a ... cent of all breast cancer cases. , The ... called invasive lobular carcinoma, gives researchers important clues ... of breast cancer, which can be missed through ... the journal PloS Genetics , was co-led ...
(Date:4/17/2014)... In the April issue of Experimental Biology ... by Drs. Rex Gaskins and Paul Kenis in ... campus of the University of Illinois Urbana-Champaign describe ... reduction-oxidation reactions underlie a variety of cell functions ... to these crucial roles in regulating normal cellular ...
(Date:4/17/2014)... Pediatrician-in-Chief Jon McCullers, MD, was recently invited to ... Nature Reviews Microbiology , one of the ... world-renowned infectious disease specialist, and chair of the ... Health Science Center, analyzed the epidemiology and microbiology ... pandemics, as well as more recent 2009 novel ...
(Date:4/17/2014)... million older Americans suffer from depression, often brought on ... research a project that followed the lives of ... found that Internet use among the elderly can reduce ... , "That,s a very strong effect," said Shelia Cotten, ... and media who led the project. "And it all ...
(Date:4/17/2014)... of Medicine (BUSM) have discovered that the anti-seizure ... model. The findings, reported in the American ... lead to more effective treatments for alcoholism. , ... leading causes of illness and death in the ... limiting the productivity of workers and necessitating huge ...
Breaking Medicine News(10 mins):Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Internet use can help ward off depression among elderly 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2
... (HealthDay News) -- Married men or those in common-law relationships ... are single, divorced or widowed, according to a new study ... receiving medical care sooner, married men are more likely to ... study,s findings could help inform the public about why prompt ...
... of the University of Granada and Edimbourgh have developed ... might improve significantly chemotherapy, as it has not cause ... encapsulation of a catalyst (palladium) into microspheres, to synthesize ... avoiding any toxicity. This system captures palladium within its ...
... from the Hebrew University have identified the molecular basis for ... this research have just been published in the journal ... genetic information required for building the proteins of the cell. ... in the cell function. These changes can lead to defects ...
... A group of French scientists (from the Unit of ... Research, Bobigny, France; the French Institute for Prevention and ... Cancer Institute) have published a paper in the ... guidelines for drinking and the relation of alcohol to ...
... the brain,s master circadian clock known as the suprachiasmatic ... rhythmic neural activity begins to decline by middle age. The ... have implications for the large number of older people who ... "Aging has a profound effect on circadian timing," said ...
... By Alan Mozes HealthDay Reporter , ... in the mid-1990s, powerful antiretroviral therapies have radically improved ... world. Now, research suggests that when made ... effective for African patients. The finding stems from ...
Cached Medicine News:Health News:Married Men Seem to Seek Help for Heart Attacks Sooner 2Health News:A new therapy without side effects could improve dramatically chemotherapy 2Health News:Hebrew U. scientists identify molecular basis for DNA breakage 2Health News:Are drinking guidelines adequate regarding the risk of cancer? 2Health News:Are drinking guidelines adequate regarding the risk of cancer? 3Health News:Study shows new evidence of age-related decline in the brain's master circadian clock 2Health News:Study shows new evidence of age-related decline in the brain's master circadian clock 3Health News:Study shows new evidence of age-related decline in the brain's master circadian clock 4Health News:Study shows new evidence of age-related decline in the brain's master circadian clock 5Health News: Drugs Can Bring HIV-Infected Africans Normal Life Spans 2Health News: Drugs Can Bring HIV-Infected Africans Normal Life Spans 3Health News: Drugs Can Bring HIV-Infected Africans Normal Life Spans 4
... (IGF-1) is a polypeptide of 70 amino acids ... of related insulin-like growth factors present in the ... with proinsulin and has a number of biological ... hormone (GH) dependent to a high degree, but ...
...
...
...
Medicine Products: